Related references
Note: Only part of the references are listed.Efficacy and Safety of Trametinib Monotherapy or in Combination With Dabrafenib in Pediatric BRAF V600-Mutant Low-Grade Glioma
Eric Bouffet et al.
JOURNAL OF CLINICAL ONCOLOGY (2023)
Pediatric low-grade glioma: Targeted therapeutics and clinical trials in the molecular era
Neevika Manoharan et al.
NEOPLASIA (2023)
Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma
Drew W. W. Rasco et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2023)
Clinical activity of pan-RAF inhibitor tovorafenib in the registrational pediatric low-grade glioma arm of the phase 2 FIREFLY-1 (PNOC026) study.
Lindsay Baker Kilburn et al.
JOURNAL OF CLINICAL ONCOLOGY (2023)
Patterns of pseudoprogression across different cancer entities treated with immune checkpoint inhibitors
Sebastian Moench et al.
CANCER IMAGING (2023)
Tackling Pediatric Low-Grade Gliomas: A Global Perspective
Daniel C. Moreira et al.
JCO Global Oncology (2023)
Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations
Eric Bouffet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2023)
Activity of Type II RAF Inhibitor Tovorafenib in a Pediatric Patient With a Recurrent Spindle Cell Sarcoma Harboring a Novel SNX8-BRAF Gene Fusion
Katharine Offer et al.
JCO Precision Oncology (2023)
CTNI-53. PNOC014: PHASE IB STUDY RESULTS OF DAY101(TOVORAFENIB) FOR CHILDREN WITH LOW-GRADE GLIOMAS (LGGS) AND OTHER RAS/RAF/MEK/ERK PATHWAY-ACTIVATED TUMORS
Karen Wright et al.
NEURO-ONCOLOGY (2022)
LTBK-04. LATE BREAKING ABSTRACT: MEK162 (binimetinib) in children with progressive or recurrent low-grade glioma: a multi-institutional phase II and target validation study
Nathan Robison et al.
NEURO-ONCOLOGY (2022)
Cobimetinib in Pediatric and Young Adult Patients with Relapsed or Refractory Solid Tumors (iMATRIX-cobi): A Multicenter, Phase I/II Study
Tanya Trippett et al.
TARGETED ONCOLOGY (2022)
CTNI-06. TRAM-01: A PHASE 2 STUDY OF TRAMETINIB FOR PATIENTS WITH PEDIATRIC GLIOMA WITH ACTIVATION OF THE MAPK/ERK PATHWAY
Sébastien Perreault et al.
NEURO-ONCOLOGY (2021)
A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study
Jason Fangusaro et al.
NEURO-ONCOLOGY (2021)
Pediatric cerebellar pilocytic astrocytoma presenting with spontaneous intratumoral hemorrhage
Carmine Antonio Donofrio et al.
NEUROSURGICAL REVIEW (2020)
Integrated Molecular and Clinical Analysis of 1,000 Pediatric Low-Grade Gliomas
Scott Ryall et al.
CANCER CELL (2020)
Pediatric low-grade glioma in the era of molecular diagnostics
Scott Ryall et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2020)
Selumetinib in Children with Inoperable Plexiform Neurofibromas
Andrea M. Gross et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Response assessment in paediatric low-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group
Jason Fangusaro et al.
LANCET ONCOLOGY (2020)
Response to trametinib treatment in progressive pediatric low-grade glioma patients
Florian Selt et al.
JOURNAL OF NEURO-ONCOLOGY (2020)
Cutaneous reactions to targeted therapies in children with CNS tumors: A cross-sectional study
Hannah Song et al.
PEDIATRIC BLOOD & CANCER (2019)
Targeting Alterations in the RAF-MEK Pathway
Rona Yaeger et al.
CANCER DISCOVERY (2019)
SIOP-E-BTG and GPOH Guidelines for Diagnosis and Treatment of Children and Adolescents with Low Grade Glioma
Astrid K. Gnekow et al.
KLINISCHE PADIATRIE (2019)
Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial
Jason Fangusaro et al.
LANCET ONCOLOGY (2019)
Oncogenic BRAF Alterations and Their Role in Brain Tumors
Felix Behling et al.
CANCERS (2019)
Mitogenic and progenitor gene programmes in single pilocytic astrocytoma cells
Zachary J. Reitman et al.
NATURE COMMUNICATIONS (2019)
Genetic Heterogeneity of BRAF Fusion Kinases in Melanoma Affects Drug Responses
Thomas Botton et al.
CELL REPORTS (2019)
Novel patterns of response under immunotherapy
E. Borcoman et al.
ANNALS OF ONCOLOGY (2019)
Efficacy and Safety of Dabrafenib in Pediatric Patients with BRAF V600 Mutation-Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa Study
Darren R. Hargrave et al.
CLINICAL CANCER RESEARCH (2019)
Neuropsychological outcomes of patients with low-grade glioma diagnosed during the first year of life
Andrew M. Heitzer et al.
JOURNAL OF NEURO-ONCOLOGY (2019)
Cardiovascular Adverse Events Associated With BRAF and MEK Inhibitors A Systematic Review and Meta-analysis
Raluca I. Mincu et al.
JAMA NETWORK OPEN (2019)
Pediatric low-grade gliomas: next biologically driven steps
David T. W. Jones et al.
NEURO-ONCOLOGY (2018)
Echocardiographic Evaluation of Ventricular Function-For the Neonatologist and Pediatric Intensivist.
Cecile Tissot et al.
FRONTIERS IN PEDIATRICS (2018)
Response Assessment in Neuro-Oncology Clinical Trials
Patrick Y. Wen et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
International incidence of childhood cancer, 2001-10: a population-based registry study
Eva Steliarova-Foucher et al.
LANCET ONCOLOGY (2017)
A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study
Anuradha Banerjee et al.
NEURO-ONCOLOGY (2017)
Comprehensive Genomic Profiling of 282 Pediatric Low- and High-Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation Signatures
Adrienne Johnson et al.
ONCOLOGIST (2017)
Ocular toxicities of MEK inhibitors and other targeted therapies
N. Stjepanovic et al.
ANNALS OF ONCOLOGY (2016)
A rare case of infantile cerebellar pilocytic astrocytoma and thrombocytopenia presenting with intratumoral hemorrhage
Shashank R. Ramdurg et al.
JOURNAL OF PEDIATRIC NEUROSCIENCES (2016)
Pilocytic astrocytoma: pathology, molecular mechanisms and markers
V. Peter Collins et al.
ACTA NEUROPATHOLOGICA (2015)
Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas
Matthias A. Karajannis et al.
NEURO-ONCOLOGY (2014)
Phase II Study of Weekly Vinblastine in Recurrent or Refractory Pediatric Low-Grade Glioma
Eric Bouffet et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Randomized Study of Two Chemotherapy Regimens for Treatment of Low-Grade Glioma in Young Children: A Report From the Children's Oncology Group
Joann L. Ater et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Long-term follow-up of the multicenter, multidisciplinary treatment study HIT-LGG-1996 for low-grade glioma in children and adolescents of the German Speaking Society of Pediatric Oncology and Hematology
Astrid K. Gnekow et al.
NEURO-ONCOLOGY (2012)
MAP Kinase Pathways
Deborah K. Morrison
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2012)
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
Patrick Y. Wen et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Share Paper
